QIAseq Pan-cancer Multimodal Panel
The only one-day, low-input sample to sequencing workflow for simultaneous and comprehensive genomic profiling of DNA variants, RNA fusions and assessing TMB/MSI in solid tumors and heme malignancies
Developed for consolidated DNA and RNA enrichment and integrated analysis, this solution has a lower sample input requirement that is ≥50% less than conventional approaches for increased compatibility with samples of limited availability. It also enables a lower overall sequencing requirement compared to separate DNA and RNA approaches, resulting in reduced per-sample costs. The QIAseq Pan-cancer Multimodal Panel provides a sample to sequencing workflow that is up to 2 days faster, with more than 50 fewer steps than similar protocols
The QIAseq Pan-cancer Multimodal Panel is intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.
Recent advances in NGS chemistries, platforms and bioinformatics pipelines are enabling users to efficiently interrogate biological samples for changes in DNA and RNA. Current approaches, however, require the use of 2 separate workflows to prepare libraries from separate DNA and RNA isolates. Limitations of such approaches include:
To overcome the limitations associated with current approaches, the QIAseq Pan-cancer Multimodal Panel starts with total nucleic acids (or DNA and RNA) as input, and generates UDI-containing, Illumina-compatible targeted DNA and RNA libraries using a single-day, consolidated workflow. In addition, the QIAseq Pan-cancer Multimodal Panel has been designed for use with low-yield and poor-quality biological samples.
Workflow of the QIAseq Pan-cancer Multimodal Panel
Learn more about the unique and innovative workflow of the QIAseq Pan-cancer Multimodal Panel.
Robust detection of DNA and RNA biomarkers
The QIAseq Pan-cancer Multimodal Panel can be used to interrogate different types of biomarkers using a consolidated workflow from total nucleic acids, which can be isolated using dedicated sample isolation protocols that have been developed specifically for the QIAseq Pan-cancer Multimodal Panel.
This innovative technology is well suited for addressing the challenges in comprehensive genomic profiling (CGP), where different types of biomarkers are assessed from a single sample. In addition, it is useful for biomarker discovery as multi-omic approaches and integrated analysis are key to providing deeper and more relevant insights.
fragment fix placeholder